Monograph Details
|
|
Ob/Gyn
> Endometriosis
|
|
ZOLADEX |
| Manufacturer |
|
AstraZeneca Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
GnRH analogue. |
| Generic Name |
|
Goserelin (as acetate) 3.6mg; SC implant. |
| Also |
|
• ZOLADEX 3-MONTH 10.8mg
|
| Indications |
|
Management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy. Endometrial thinning prior to endometrial ablation for dysfunctional uterine bleeding. |
| Children |
|
<18years: not applicable. |
| Adults |
|
Implant SC into anterior abdominal wall. ≥18years: Endometriosis: one 3.6mg implant every 28 days, for up to 6 months. Retreatment: not recommended. Endometrial thinning: one 3.6mg implant, do surgery at 4 weeks. Or, may give a second 3.6mg implant 4 weeks after the first, and do surgery 2–4 weeks after the second implant. |
| Contraindications |
|
Pregnancy (Cat.X). Nursing mothers. |
| Precautions |
|
Nondiagnosed abnormal vaginal bleeding: not recommended. Use nonhormonal contraception during and for 12 weeks after discontinuation of drug or until menses resume. Risk factors for decreased bone mineral density (eg, chronic alcohol, tobacco, anticonvulsants, corticosteroids). Hyperlipidemia. |
| Interactions |
|
May affect tests of pituitary-gonadotropic and gonadal functions. |
| Adverse Reactions |
|
Endometriosis: hot flashes, vaginitis, headache, emotional lability, change in libido/breast size, depression, sweating, amenorrhea. Endometrial thinning: headache, hot flashes, hypertension, vulvovaginitis, increased cervical resistance. |
| How Supplied |
|
Implant (in syringe)—1 |
|
|
|
|
